Skip to main content
Tempus AI10-Q: AI investment

Tempus Collaborates with AstraZeneca and Pathos to Build Foundation Multimodal Oncology AI Model

Source: Autobound Signal API · 98 signals tracked for Tempus AI · updated

Get Tempus AI's live signals in Claude or ChatGPT, or by API

AskWhat changed at Tempus AI this week? Use Autobound signals for tempus.com.

What happened

Tempus entered agreements with AstraZeneca and Pathos to develop and validate a foundation large multimodal model in oncology using de-identified datasets. In October 2026, Tempus paid Pathos $10.0 million as part of its $35.0 million commitment to support the model's development.

Source

SEC EDGARNov 2, 2026

Quarterly report (Form 10-Q)

Tempus AI 10-Q for Quarter ended Sep 30, 2026

Filing excerpt

Pursuant to the MSA, (i) we will ensure that Pathos develops, and we provide AstraZeneca with, a Foundation Model which has been developed, validated, and maintained using de-identified datasets contributed by us, (ii) the Foundation Model will be developed, validated, and maintained by Pathos, (iii) AstraZeneca has paid us a fee of $35.0 million, and (iv) a syndicate of investors including AstraZeneca will contemporaneously execute a Stock Purchase Agreement with Pathos, or the SPA, as part of a preferred stock financing round of sufficient size given the obligations described herein.

sec.gov/Archives/edgar/data/1717115/000119312526442624/tem-20260930.htmRead the full source

Other signals in this filing (4)

Extracted by Autobound

From the Signal API record
Signal
10-Q: AI investment

What this signalsFilings often name leadership changes, deals and spending plans.

Period
Quarter ended Sep 30, 2026
Fiscal year end
09/30
Filed
Nov 2, 2026

More 10-Q signals at other companies

The full record

From the Signal API record

Numbers

Dollar figure
$10M (paid to Pathos in October 2026 under the Pathos Master Agreement for Foundation Model commitments)

Details

CIK
1717115
Accession number
0001193125-26-442624
Timeframe
Current quarter
Quarter
Q3
Filing year
2026
Period end date
Sep 30, 2026
Why it matters
Target for AI vendors
Signal category
Technology

Topics and mentions

Technologies

  • foundation large multimodal model
  • AI

Vendors

  • Pathos

Extraction

Confidence
High
Relevance
85%
Sentiment
Positive
Detected
Nov 3, 2026
signal_type
sec-10q
signal_subtype
aiInvestment

Use this data

Get every 10-Q signal for Tempus AI and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Tempus AI this week?”

  2. Send it to your own tools

    The Signal API returns 10-Q signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full sec-10q record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/55632bcf-8fc0-4d0d-b6db-5009f295cead returns this record as JSON. POST /v1/companies/enrich returns every signal for tempus.com.

{
  "signal_id": "55632bcf-8fc0-4d0d-b6db-5009f295cead",
  "signal_type": "sec-10q",
  "signal_subtype": "aiInvestment",
  "detected_at": "2026-11-03T07:10:20.294+00:00",
  "company": {
    "name": "Tempus AI",
    "domain": "tempus.com"
  },
  "data": {
    "detail": "Tempus entered agreements with AstraZeneca and Pathos to develop and validate a foundation large multimodal model in oncology using de-identified datasets. In October 2026, Tempus paid Pathos $10.0 million as part of its $35.0 million commitment to support the model's development. This initiative may create opportunities for AI infrastructure, compute, and specialized ML tool providers.",
    "metrics": {
      "timeframe": "current_quarter",
      "dollar_context": "paid to Pathos in October 2026 under the Pathos Master Agreement for Foundation Model commitments",
      "dollar_millions": 10
    },
    "quarter": "Q3",
    "summary": "Tempus Collaborates with AstraZeneca and Pathos to Build Foundation Multimodal Oncology AI Model",
    "excerpts": "Pursuant to the MSA, (i) we will ensure that Pathos develops, and we provide AstraZeneca with, a Foundation Model which has been developed, validated, and maintained using de-identified datasets contributed by us, (ii) the Foundation Model will be developed, validated, and maintained by Pathos, (iii) AstraZeneca has paid us a fee of $35.0 million, and (iv) a syndicate of investors including AstraZeneca will contemporaneously execute a Stock Purchase Agreement with Pathos, or the SPA, as part of a preferred stock financing round of sufficient size given the obligations described herein.",
    "relevance": 0.85,
    "sentiment": "positive",
    "confidence": "high",
    "source_url": "https://www.sec.gov/Archives/edgar/data/1717115/000119312526442624/tem-20260930.htm",
    "filing_date": "2026-11-02",
    "filing_year": 2026,
    "fiscal_year": 2026,
    "fiscal_year_end": "09/30",
    "period_end_date": "2026-09-30",
    "sales_relevance": "Target for AI vendors",
    "signal_category": "technology",
    "vendors_mentioned": [
      "Pathos"
    ],
    "technologies_mentioned": [
      "foundation large multimodal model",
      "AI"
    ]
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.